id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-018040-k0h5ejjt	Ilyinskii, P.	Aspects of Microparticle Utilization for Potentiation of Novel Vaccines: Promises and Risks	2009		.txt	text/plain	6930	309	41	Many recombinant vaccines against novel (HIV, HCV) or ever-changing (influenza) infectious agents require the presence of adjuvants/delivery vehicles to induce strong immune responses. Cationic and anionic polylactide co-glycolide (PLG) microparticles have been successfully used to adsorb a variety of agents, which include plasmid DNA, recombinant proteins and adjuvant active oligonucleotides and are also currently tested in several vaccine applications. The size of these vectors is generally within 10-1000 nm and it is a specific mechanism by which our immune system recognizes such particles that underlies their adjuvant potencies (in addition, many carriers protect proteins/NA from rapid degradation in vivo and release them into the organism during prolonged periods of time, which also results in higher immunogenicity). Several VLPbased vaccines have been licensed for general use, many of them against HBV, which are composed of HBV surface antigen (HBsAg), which is a main component of currently used protein-based, alum adjuvant-potentiated vaccine.	./cache/cord-018040-k0h5ejjt.txt	./txt/cord-018040-k0h5ejjt.txt